Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Targets |
Fluorescent Dye; Emission (Em) = 515; Excitation (Ex) = 489
|
---|---|
ln Vitro |
In coelomic fluid or ISO-EDTA-incubated coelomocytes, calcein builds up. Calcine fluorescence intensity was higher in coelomic cells cultured in CF as compared to control cultures.
|
Enzyme Assay |
Coelomocytes and hemocytes were stained with the ABC transporter substrate calcein-AM and dye accumulation analyzed under flow cytometry. Reversin 205 (ABCB1 transporter blocker) and MK571 (ABCC1 transporter blocker) were used as pharmacological tools to investigate ABC transporter activity. A different pattern of calcein accumulation was observed in coelomocytes: phagocytes > colorless spherulocytes > vibrate cells > red spherulocytes. The treatment with MK571 increased calcein fluorescence levels in coelomocytes from both species. However, reversin 205 treatment was not able to increase calcein fluorescence in E. esculentus coelomocytes. These data suggest that ABCC1-like transporter activity is present in both sea urchin species, but ABCB1-like transporter activity might only be present in E. lucunter coelomocytes. The activity of ABCC1-like transporter was observed in all cell types from both bivalve species. However, reversin 205 only increased calcein accumulation in hyalinocytes of the oyster C. gasar, suggesting the absence of ABCB1-like transporter activity in all other cell types, including hyalinocytes from the oyster C. gigas. Additionally, our results showed that C. gigas exhibited higher activity of ABCC1-like transporter in all hemocyte types than C. gasar. The present work is the first to characterize ABCB1 and ABCC1-like transporter activity in the immune system cells of sea urchins E. lucunter and E. esculentus and oysters. Our findings encourage the performing studies regarding ABC transporters activity/expression in immune system cells form marine invertebrates under stress conditions and the possible use of ABC transporters as biomarkers[1].
|
Cell Assay |
Examples:
Calcein is a fluorescent probe with yellow green fluorescence, and may be used to determine labile iron pool and measure the Fe(III)-binding affinity with ligands. Method: For cell staining. 1. Cells (10~6/mL) are loaded by incubation with 20 µM Fe(II) for 2 h at 37°C. 2. Cells are collected by centrifugation (1000 rpm; 5 min) and incubated with Calcein (0.5 µM; 15 min; 37°C) in a D’hanks buffer (pH 7.4). 3. Wash cells for twice by D’hanks buffer (pH 7.4). 4. The fluorescence is monitored by both flow cytometry and a confocal laser scanning microscope. Description: Calcein is a fluorescent probe with yellow green fluorescence, and may be used in capillary-like tube formation assay. Method: For cell staining. 1. Cells are seeded at a density of 5×104 cells/well into Matrigel coated 96-well plates and treated with conditioned medium for 5.5 h under normoxia or hypoxia. 2. Stain cells with Calcein (0.5 h). 3. Tubes forming intact networks are captured by Lion Heart (Biotec) and quantified by counting the number of tubes. Description: Calcein is a fluorescent probe with yellow green fluorescence, and may be used in tube formation assay. Method: For cell staining. 1. Suspend cultured cells in conditioned medium and seeded into Matrigel coated 96-well plates at a density of 5×104 cells/well for 6 h under normoxia or hypoxia. 2. Stain cells with Calcein (10 min). 3. Tubes forming intact networks are captured by Lion Heart and quantified by the tube length and number of branch points using Image J. |
References | |
Additional Infomation |
Calcein is a xanthene dye. It has a role as a fluorochrome. It is functionally related to a fluoran.
Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent. |
Exact Mass |
622.143
|
---|---|
Elemental Analysis |
C, 57.88; H, 4.21; N, 4.50; O, 33.41
|
CAS # |
1461-15-0
|
Related CAS # |
Calcein (tetraethyl ester);1170856-93-5
|
PubChem CID |
65079
|
Appearance |
Yellow to orange solid powder
|
Density |
1.7±0.1 g/cm3
|
Boiling Point |
952.7±65.0 °C at 760 mmHg
|
Melting Point |
200 °C
|
Flash Point |
530.0±34.3 °C
|
Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
Index of Refraction |
1.775
|
LogP |
1.56
|
Hydrogen Bond Donor Count |
6
|
Hydrogen Bond Acceptor Count |
15
|
Rotatable Bond Count |
12
|
Heavy Atom Count |
45
|
Complexity |
1070
|
Defined Atom Stereocenter Count |
0
|
SMILES |
O1C(C2=C([H])C([H])=C([H])C([H])=C2C21C1C([H])=C(C([H])([H])N(C([H])([H])C(=O)O[H])C([H])([H])C(=O)O[H])C(=C([H])C=1OC1C([H])=C(C(C([H])([H])N(C([H])([H])C(=O)O[H])C([H])([H])C(=O)O[H])=C([H])C2=1)O[H])O[H])=O
|
InChi Key |
DEGAKNSWVGKMLS-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C30H26N2O13/c33-21-7-23-19(5-15(21)9-31(11-25(35)36)12-26(37)38)30(18-4-2-1-3-17(18)29(43)45-30)20-6-16(22(34)8-24(20)44-23)10-32(13-27(39)40)14-28(41)42/h1-8,33-34H,9-14H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)
|
Chemical Name |
2-[[7'-[[bis(carboxymethyl)amino]methyl]-3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-2'-yl]methyl-(carboxymethyl)amino]acetic acid
|
Synonyms |
Fluorexon; 1461-15-0; Oftasceine; Oftasceinum; Oftasceina; 2,2',2'',2'''-(((3',6'-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-2',7'-diyl)bis(methylene))bis(azanetriyl))tetraacetic acid; Oftasceine [INN];
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
0.1 M NaOH : ~10 mg/mL (~16.06 mM)
DMSO : ~5 mg/mL (~8.03 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (0.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 20 mg/mL (32.13 mM) in 2% NaHCO3 in ddH2O (add these co-solvents sequentially from left to right, and one by one), clear solution; Need ultrasonic and adjust pH to 6 with NaHCO3.  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01892670 | COMPLETED | Other: Donation of 1 whole blood unit | Austere Environment Blood Bank Buddy Transfusion Trauma |
Haukeland University Hospital | 2013-03 | Not Applicable |
NCT05948930 | RECRUITING | Behavioral: Progressive aerobic exercise Behavioral: Adaptive cognitive training Behavioral: Combined |
Mild Cognitive Impairment | University of Maryland, Baltimore | 2024-01-08 | Not Applicable |